The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
Medicinal Research Reviews · 2024-03 · 44 (2) · 632-685
DOI: 10.1002/med.21992 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 20.11.2023. Verfasst von Xuewu Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Hauptthemen laut MEDLINE: Drug Development. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 210 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Lingang Laboratory.
Abstract (Originalsprache)
Imbalances in protein and noncoding RNA levels in vivo lead to the occurrence of many diseases. In addition to the use of small molecule inhibitors and agonists to restore these imbalances, recently emerged targeted degradation technologies provide a new direction for disease treatment. Targeted degradation technology directly degrades target proteins or RNA by utilizing the inherent degradation pathways, thereby eliminating the functions of pathogenic proteins (or RNA) to treat diseases. Compared with traditional therapies, targeted degradation technology which avoids the principle of traditional inhibitor occupation drive, has higher efficiency and selectivity, and widely expands the range of drug targets. It is one of the most promising and hottest areas for future drug development. Herein, we systematically introduced the in vivo degradation systems applied to degrader design: ubiquitin–proteasome system, lysosomal degradation system, and RNA degradation system. We summarized the development progress, structural characteristics, and limitations of novel chimeric design technologies based on different degradation systems. In addition, due to the lack of clear ligand‐binding pockets, about 80% of disease‐associated proteins cannot be effectively intervened with through traditional therapies. We deeply elucidated how to use targeted degradation technology to discover and design molecules for representative undruggable targets including transcription factors, small GTPases, and phosphatases. Overall, this review provides a comprehensive and systematic overview of targeted degradation technology‐related research advances and a new guidance for the chimeric design of undruggable targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
- School of Pharmacy, Fudan University, Shanghai, China.
ORCID-Profile: Xuewu Liang, Fengyang Han, Hong Liu
Förderung
- National Natural Science Foundation of China
- Lingang Laboratory
Zitieren
APA
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2024). The new direction of drug development: Degradation of undruggable targets through targeting chimera technology. Medicinal Research Reviews, 44(2), 632-685. https://doi.org/10.1002/med.21992
Vancouver
Liang X, Ren H, Han F, Liang R, Zhao J, Liu H. The new direction of drug development: Degradation of undruggable targets through targeting chimera technology. Medicinal Research Reviews. 2024;44(2):632-685. doi:10.1002/med.21992
BibTeX
@article{Liang2024,
author = {Liang, Xuewu and Ren, Hairu and Han, Fengyang and Liang, Renwen and Zhao, Jiayan and Liu, Hong},
title = {The new direction of drug development: Degradation of undruggable targets through targeting chimera technology},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {2},
pages = {632--685},
doi = {10.1002/med.21992}
}
EUVIMED